• Explore /
  • Poster
  • / Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.

Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.

Abstract Poster

Authors

null

Jean-Luc Van Laethem

Erasme University Hospital, Brussels, Belgium

Jean-Luc Van Laethem , Jacek Jassem , Volker Heinemann , Colin D. Weekes , John A. Bridgewater , Stefano Cascinu , Bohuslav Melichar , Marc Peeters , Paul J. Ross , Piotr Saramak , Marius Giurescu , Vittorio Luigi Garosi , Katrin Roth , Anke Schulz , Michael Teufel , Barrett H. Childs , Hanno Riess

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01251640

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 4025)

DOI

10.1200/jco.2014.32.15_suppl.4025

Abstract #

4025

Poster Bd #

44

Abstract Disclosures

Similar Posters

First Author: Hanno Riess

First Author: Vincent M. Chung

First Author: Jean-Luc Van Laethem

First Author: Chuanliang Cui